A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
- Cancer
- Solid Tumors
Recruiting
- Argentina
- Austria
- Brazil
- Canada
- Chile
- Colombia
- Egypt
- Estonia
- France
- Germany
- Greece
- India
- Ireland
- Israel
- Lebanon
- Mexico
- Philippines
- Poland
- Portugal
- Saudi Arabia
- Serbia
- Slovakia
- Slovenia
- South Africa
- Spain
- Taiwan
- Thailand
- Türkiye
- United Arab Emirates
- United Kingdom
- Vietnam
NCT04529122 MX39897
Trial Summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
Eligibility Criteria
- Participant is an adult (according to the age of majority as defined by local regulations)
- Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
- Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
- Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
- Participant has a prior or current diagnosis of haematological malignancy
For the latest version of this information please go to www.forpatients.roche.com